Poly Medicure Limited Reports Fourth Quarter & FY 2025 Results
Quarterly and FY 25 Consolidated Revenue growth of 17% and 21% respectively on a YoY basis FY 25 Consolidated EBITDA growth of 27% on a YoY basis, Q4 Core EBITDA margin 27.1% Consolidated Quarterly and yearly PAT
Quarterly and FY 25 Consolidated Revenue growth of 17% and 21% respectively on a YoY basis
FY 25 Consolidated EBITDA growth of 27% on a YoY basis, Q4 Core EBITDA margin 27.1%
Consolidated Quarterly and yearly PAT Growth of 34% and 31% respectively on a YoY basis; Q4 PAT
margin of 20.8%
Poly Medicure Ltd. (NSE: POLYMED | BSE: 531768), India’s leading Medical
Device company with a dominant position in medical consumables market, announced its audited
consolidated and standalone financial results for the quarter and year ended on March 31st, 2025.
Key Financial Summary:
| Consolidated Rs. Crores | Q4 2025 | Q4 2024 | YoY Growth (%) | FY 2025 | FY 2024 | YoY Growth (%) |
| Consolidated Revenue from Operations | 440.8 | 378.1 | 16.6% | 1669.8 | 1375.8 | 21.4% |
| EBITDA | 119.5 | 96.5 | 23.8% | 452.8 | 357.7 | 26.6% |
| EBITDA Margin | 27.1% | 25.5% | +160BPS | 27.1% | 26.0% | +113BPS |
| Profit after Tax | 91.8 | 68.4 | 34.3% | 338.6 | 258.3 | 31.1% |
| PAT Margin | 20.8% | 18.1% | +270BPS | 20.3% | 18.8% | +150BPS |
| EPS – Basic | 8.9 | 7.1 | 25.2% | 34.1 | 26.9 | 26.8% |
Key Financial Highlights:
- Revenue from operations increased by 17% in Q4 2025 compared to Q4 2024; FY2025 revenue growth stood at 21%.
- Export revenue for FY2025 increased by 24% YoY, driven by continued strong performance in key international markets. Geopolitical tensions and tariff war creating short term demand uncertainty in certain export markets.
- The domestic quarterly and yearly revenue growth was 24% and 19% respectively on a YoY basis, domestic revenue growth has shown strong traction as the year progressed.
- Renal division continues to gain market share in the domestic market with revenue growth of 69% and 60% in Q4 and FY2025 period respectively.
- EBITDA grew by 24% in Q4 2025 on a YoY basis, reflecting our strong earnings capability from core operations. The EBITDA margins improved by 160BPS to 27% in Q4 2025.
- Profit After Tax (PAT) increased by 34% in Q4 2025 compared to Q4 2024, ; PAT margin expanded by almost 270BPS to 21% in Q4 2025.
- The balance sheet position remains strong with liquidity position of Rs. 1220crs as at March 25
- Adjusted RoCE* was 23.4% for FY 25 as compared to 23% in the corresponding previous financial year
- Incurred a CAPEX of Rs. 325crs in FY 25 reflecting our commitment to create adequate infrastructure to capture future growth opportunities in the sector.
* Excludes the impact of amount raised through QIP in August 2024, EBIT has been computed after excluding the treasury income generated from the QIP Funds; calculated on the basis of Standalone Financial Statement
Commenting on the results for the quarter, Mr. Himanshu Baid, Managing Director, Poly Medicure Limited stated:
We are extremely pleased with our continued growth in the business in the Q4 and FY2025. Our margins continue to expand at higher scale of operations and that gives us immense confidence to keep investing capital to create additional manufacturing capacities.
FY 2025 has been a transformative year for Polymed as we commercialised two new divisions, Cardiology and Critical Care. Our renal division continues to grow from strength to strength while the core infusion therapy consolidates its leadership position in clinically driven segments.
The current ongoing geopolitical condition as well as uncertainty created due to US imposed tariffs may create short term pressure on demand in certain export markets. We believe that India MedTech sector is well-positioned to benefit from this situation on a longer term basis as global customers look to create alternate supply chains.
Our investment in 3 new plants is going on strongly, which we believe positions us very strongly to achieve the significant growth opportunities that lie in front of us.
